Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
May 6, 2020

PrecisionLife uses AI to identify drug candidates for Covid-19-induced sepsis

By Chloe Kent

Data scientists from UK artificial intelligence (AI) company PrecisionLife have identified 59 repurposing drug candidates that could potentially treat patients who develop sepsis while suffering from severe Covid-19.

The study, released today on open-access repository bioRxiv, sought to identify genetic risk factors for sepsis in the context of Covid-19. These insights were then used to identify existing drugs that might be used to treat life-threatening late-stage disease.

Sepsis is observed in around 60% of severe Covid-19 patients, the company said.

The PrecisionLife team has identified mutations in 70 sepsis risk genes, 61% of which were also present specifically in severe Covid-19 patients. Of these genes, 13 are known to be druggable, with 59 compounds and drugs known to be active against these 13 targets.

These compounds could now form the basis for future drug trials and repurposing projects.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy